The study, published in BMC Pharmacology and Toxicology, used several complementary measurements to characterize how the combination affected the cancer cells. In addition to the MTT viability assay, the researchers used Annexin V and propidium iodide staining to detect apoptosis, examined cell-cycle distribution and employed quantitative real-time PCR to assess expression of genes associated with apoptosis, resistance to apoptosis and inflammation. An oxidative-stress assay measured glutathione levels. OEC normal epithelial cells served as controls for the in vitro experiments.

Among the clearest findings was that ivermectin attenuated cisplatin-induced S-phase arrest in HN9 cells. Cisplatin alone increased the proportion of cells associated with S-phase arrest, while the combination reduced that response compared with cisplatin monotherapy. The combination was also associated with lower expression of the pro-apoptotic markers BAX and caspase-3 than cisplatin alone. These measured changes were consistent with the lower cytotoxicity observed in the viability assay. Together, the results show that ivermectin interfered with several cellular responses associated with cisplatin in this experimental model, rather than strengthening them.

The treatments also produced differential changes in two measures connected with inflammation and oxidative stress. Expression of tumor necrosis factor alpha, or TNF-α, and cellular glutathione levels varied across the single-drug and combination conditions. The researchers suggested that ivermectin’s antioxidant and anti-inflammatory properties may contribute to its antagonistic interaction with cisplatin. That proposed explanation was not isolated by the experiments, and the results do not establish which molecular process produced the antagonism. The study instead links the reduced cytotoxicity with attenuated S-phase arrest and diminished expression of pro-apoptotic markers while leaving the full mechanism unresolved.

These findings are limited to an in vitro study of one oral cancer cell line, with normal epithelial cells included as controls. The research does not demonstrate a clinical treatment effect, and it does not show how ivermectin and cisplatin would interact in patients. The authors stated that further investigations are needed to clarify the underlying molecular mechanisms and determine whether similar effects occur in other oral cancer models or in vivo settings. Within the tested HN9 cells, however, the evidence demonstrates that ivermectin reduced rather than amplified the cytotoxic, pro-apoptotic and cell-cycle-arresting effects associated with cisplatin.

Subject of Research: Antagonistic interaction between ivermectin and cisplatin in HN9 oral squamous cell carcinoma cells.

Article Title: When drug repurposing backfires: antagonistic effects of ivermectin on cisplatin therapy in oral cancer

Article References: Tantawy, R., Raafat, S. N., El-Gawish, A., & Ghalwash, D. (2026). When drug repurposing backfires: antagonistic effects of ivermectin on cisplatin therapy in oral cancer. BMC Pharmacology and Toxicology. https://doi.org/10.1186/s40360-026-01198-w

Image Credits: AI Generated

DOI: 10.1186/s40360-026-01198-w

Keywords: ivermectin, cisplatin, oral cancer, drug repurposing, drug antagonism, cell viability, apoptosis, cell-cycle arrest, oxidative stress, cancer cell lines, drug, repurposing

Histone deacetylase inhibitors represent one of the most actively explored classes of epigenetic anticancer agents. These drugs block enzymes that remove acetyl groups from histone proteins, the spools around which DNA is wound. When acetylation is preserved, chromatin stays in an open, transcriptionally permissive state, allowing genes that restrain tumor growth to be expressed. Aberrant deacetylation is a hallmark of many cancers, including colorectal cancer, where it silences tumor suppressor pathways and promotes uncontrolled cell division. Prior studies have shown that HDAC inhibitors can trigger cell cycle arrest, differentiation, and even programmed cell death in a range of tumor types, from glioblastoma to gastric cancer, and givinostat itself has already been tested in humans for inflammatory and blood disorders.

To probe how ITF2357 affects colorectal cancer cells, the researchers turned to CT26, a mouse colon carcinoma cell line widely used in preclinical oncology. In laboratory cultures, the drug significantly reduced cell viability and proliferation and dramatically impaired the ability of cells to form colonies, a measure of long-term reproductive fitness. Flow cytometry analysis of the cell cycle revealed that treated cells accumulated in the G0/G1 phase, the resting and early growth stage of the cell cycle, indicating that ITF2357 prevents cells from committing to DNA replication. This kind of arrest is a classic anti-proliferative signature and suggests the drug halts tumor expansion by keeping cells locked out of the division program rather than by causing immediate toxicity.

The team then moved from the dish to living organisms. They established subcutaneous CT26 tumors in female BALB/c mice and treated the animals with ITF2357. The drug markedly suppressed tumor growth over the course of the experiment. Critically, the treated mice showed no loss of body weight and no observable damage to liver or kidney tissue, two organs whose health is a standard barometer of systemic toxicity. This safety profile is particularly notable because many anticancer agents fail at this hurdle, and it suggests that ITF2357 can discriminate between tumor cells and normal tissue at the doses tested, at least in this model.

What makes the new study stand out is the depth of its molecular detective work. Rather than stopping at the observation that the drug works, the researchers deployed a multi-omics strategy to trace exactly how it acts. They performed miRNA sequencing to catalogue the small RNAs whose expression changes after treatment, mRNA sequencing to capture the downstream gene expression shifts, and ATAC-seq, a technique that maps open chromatin regions genome-wide and reveals where the transcriptional machinery has gained or lost access to DNA. Integrating these three layers of data allowed the team to pinpoint candidate regulatory molecules that connect the epigenetic action of the drug to its biological effects.

The analysis converged on a striking finding: ITF2357 treatment upregulated miR-1938, a microRNA that had not previously been implicated in the response to HDAC inhibitors in colorectal cancer. MicroRNAs are short non-coding RNAs, roughly 20 to 24 nucleotides long, that regulate gene expression after transcription. Each microRNA binds to complementary sequences in the 3-prime untranslated region, or 3′-UTR, of target messenger RNAs, blocking their translation into protein or hastening their degradation. Through this post-transcriptional gatekeeping, a single microRNA can restrain an entire network of cancer-promoting genes. The researchers validated the interaction experimentally using a dual-luciferase reporter assay, which confirmed that miR-1938 binds directly to the 3′-UTR of ADAM12 messenger RNA and suppresses its output.

ADAM12 belongs to a family of transmembrane metalloproteases involved in shedding growth factors, remodeling the extracellular matrix, and driving invasive behavior in tumors. Elevated ADAM12 expression has been linked to poor outcomes in liver cancer and colon adenocarcinoma, and it has been implicated in tumor angiogenesis through STAT3 signaling. The new study adds a crucial layer to this picture by showing that ADAM12 is a direct functional target of the drug response. When the researchers knocked down ADAM12 with RNA interference in CT26 cells, the effects mirrored those of ITF2357 treatment: proliferation dropped and cells accumulated in the G0/G1 phase. This phenocopy experiment is a powerful piece of evidence that suppressing ADAM12 is not merely a side effect of the drug but a central mechanism through which it stalls tumor growth.

The clinical relevance of the axis was reinforced by prognostic data. The team found that colorectal cancer patients with high ADAM12 expression in their tumors had significantly worse outcomes, consistent with earlier reports that ADAM12 upregulation correlates with poor survival and altered immune cell infiltration in colon adenocarcinoma. This means the miR-1938/ADAM12 axis is not just a laboratory curiosity but a molecular signature that tracks with real patient prognosis, raising the possibility that ADAM12 could serve as both a biomarker for identifying patients likely to benefit from HDAC inhibitor therapy and a therapeutic target in its own right.

From a translational standpoint, the study arrives at an interesting moment for givinostat. The drug has a documented pharmacokinetic and safety profile from phase 1 trials in humans, where it was administered orally and shown to modulate inducible cytokine responses. It has been explored in chronic myeloproliferative neoplasms carrying the JAK2V617F mutation, in acute myeloid leukemia cells, and in glioblastoma models where it reversed transformed phenotypes and countered cancer stemness. The new colorectal cancer data extend this portfolio and, importantly, identify a specific microRNA-mediated mechanism that could be monitored in future trials as a pharmacodynamic readout of drug activity.

The researchers caution that their findings come from cell culture and a mouse xenograft model, and that translating these results into human therapy will require further validation, including studies in patient-derived models and eventually clinical trials. Nevertheless, the work establishes a clear causal chain from an epigenetic drug to a microRNA to a cancer-driving protease to a cell cycle checkpoint, and it does so with the kind of multi-omics rigor that is increasingly expected in modern cancer pharmacology. For a disease as prevalent and lethal as colorectal cancer, the identification of a druggable axis that can be engaged by an already clinically tested molecule is a meaningful step forward, and it provides a foundation for exploring ITF2357 as a therapeutic option in patients whose tumors depend on the ADAM12 pathway.

Subject of Research: Pharmacology and molecular oncology of colorectal cancer

Article Title: ITF2357 exerts anti‑tumor activity in colorectal cancer via the miR‑1938/ADAM12 axis

Article References: Wang, T., Zhang, L., Yakupu, Z., Shi, X., Maimaiti, Y., Salikebai, B., Mahemuti, M., Xiao, H., Daoken, Y., Wang, Z., Zhang, B., & Jiapaer, Z. (2026). ITF2357 exerts anti‑tumor activity in colorectal cancer via the miR‑1938/ADAM12 axis. Molecular Biology Reports, 53(1), Article 1753. https://doi.org/10.1007/s11033-026-12944-y

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12944-y

Keywords: colorectal cancer, givinostat, ITF2357, HDAC inhibitor, miR-1938, ADAM12, cell cycle arrest, epigenetics, microRNA, multi-omics, tumor suppressor, drug mechanism

One of the more striking aspects of this study is the breadth of its screening strategy. Rather than testing the proline analogues against a single laboratory strain, the researchers evaluated decyl-, oleyl-, and farnesyl-substituted compounds across all six discrete typing units of T. cruzi, the classification scheme that captures the remarkable genetic and geographic diversity of this parasite across the Americas. This matters because susceptibility to chemotherapeutic agents can vary substantially between DTUs, and a candidate compound that works well against one strain but fails against others offers limited real-world promise. The broad-spectrum activity observed here suggests that proline uptake is not a strain-specific vulnerability but a shared metabolic dependency, which strengthens the case for the TcAAAP069 transporter and related permeases as therapeutic targets.

The distinction between cytostatic and cytotoxic outcomes is also worth emphasizing. Flow cytometry revealed that compound 2, bearing an oleyl chain, pushed parasites toward an apoptosis-like death phenotype, whereas compounds 1 and 3, with decyl and farnesyl chains respectively, halted the cell cycle at the G1 phase without immediately killing the parasites. This kind of mechanistic divergence from relatively small structural changes is a classic hallmark of polypharmacology, where lipophilic tails of different lengths and degrees of unsaturation interact with different membrane compartments or intracellular targets. The farnesyl group is particularly interesting because isoprenoid moieties are already exploited in other antiparasitic strategies, and their presence here may allow compound 3 to interfere with sterol biosynthesis or protein prenylation pathways in addition to proline transport.

The fluorescent labeling experiment provides a methodological lesson that extends beyond this specific parasite. By attaching an NBD fluorophore to compound 1, the team could directly observe whether the analogue actually entered epimastigotes rather than merely sitting on the surface. Fluorescence microscopy confirmed internalization, which is a crucial piece of evidence for the hypothesis that these molecules hijack the parasite’s own amino acid permeases as entry routes. If proline analogues are indeed ferried across the plasma membrane by the very transporters they inhibit, this creates a self-defeating mechanism for the parasite: the more it tries to import proline, the more inhibitor it accumulates internally. Such Trojan-horse behavior is highly desirable in antiparasitic drug design, where achieving adequate intracellular concentrations is often the limiting factor.

The structure-activity relationship work with compounds 4 through 13 adds a rational design dimension to the study. The finding that the triazole motif is essential for activity while the proline moiety confers selectivity suggests a modular architecture in which each fragment performs a distinct role. Triazoles are ubiquitous in medicinal chemistry, partly because of their metabolic stability and their capacity to engage in hydrogen bonding and dipolar interactions with biological targets. In this context, the triazole may serve as the pharmacophoric element that interacts with the permease binding site, while the proline head acts as a recognition handle that biases uptake toward parasite transporters rather than mammalian ones. The absence of the TcAAAP family in mammals is what underpins this selectivity argument, and it is one of the most compelling aspects of targeting this transporter family.

It is also worth situating these findings within the broader landscape of Chagas disease chemotherapy. The two drugs currently in use, nifurtimox and benznidazole, were developed more than half a century ago and rely on nitroheteroaryl chemistry that generates reactive intermediates inside the parasite. While effective in acute infections, their performance in the chronic phase is inconsistent, and side effects frequently complicate long-term treatment. A strategy that instead starves the parasite of a key amino acid or poisons its uptake machinery operates through an entirely different mechanism, which means it could in principle be combined with existing nitroheterocycles to achieve additive or synergistic effects. Metabolic targets also tend to be more conserved across parasite stages, offering potential utility against both replicating intracellular amastigotes and the more drug-tolerant trypomastigote forms.

The metabolic logic underlying proline dependence in T. cruzi deserves further elaboration. Proline is not merely a building block for proteins in this organism; it functions as a carbon and nitrogen source, an electron donor feeding the mitochondrial respiratory chain, a precursor for glutamate and downstream Krebs cycle intermediates, and a component of the parasite’s oxidative stress defense. The two-step oxidation of proline to glutamate, catalyzed by proline dehydrogenase and P5C dehydrogenase, feeds reducing equivalents directly into the electron transport chain, and the resulting glutamate can be transaminated to alpha-ketoglutarate for entry into central carbon metabolism. Disrupting the supply of proline at the transporter level therefore has cascading consequences that touch energy production, redox balance, osmoregulation, and differentiation programs such as metacyclogenesis.

From a drug discovery perspective, the observation that different alkyl chains produce different phenotypic outcomes opens a productive line of inquiry. Decyl and oleyl chains differ not only in length but in saturation, and membrane fluidity is known to affect transporter conformation and function. It is plausible that the oleyl compound partitions more deeply into lipid rafts or mitochondrial membranes, perturbing membrane potential and triggering the apoptotic-like markers observed by flow cytometry, while the shorter decyl chain allows the molecule to remain more closely associated with the permease and act primarily as a transport blocker. Disentangling these possibilities will likely require follow-up experiments with purified transporters in heterologous systems, as well as lipidomics to see whether the analogues remodel membrane composition in ways that contribute to their effects.

The study also highlights a broader principle in chemical biology: the value of chemical probes as complements to genetic approaches. Knocking out or silencing a gene in T. cruzi is technically challenging and often produces compensatory adaptations over the course of parasite propagation. Small molecule inhibitors, by contrast, can be applied acutely and at defined concentrations, allowing researchers to observe the immediate physiological consequences of transport inhibition before the parasite has had time to rewire its metabolism. The tuneable and reversible nature of pharmacological interference makes it possible to build dose-response relationships and to distinguish primary effects from secondary downstream consequences, which is precisely what this study leverages in delineating cytostasis from cytotoxicity.

Looking forward, several questions emerge from this work that could shape the next phase of investigation. First, does the selectivity conferred by the proline moiety hold up in mammalian cell lines, and what is the therapeutic window in infected host cells? Second, can the fluorescent probe approach be extended to intracellular amastigotes, the clinically most relevant stage, to confirm that uptake occurs in the mammalian context as well as in cultured epimastigotes? Third, are there additional members of the TcAAAP family that these analogues engage, and could simultaneous inhibition of multiple permeases produce stronger or more durable effects? Fourth, does prolonged exposure select for resistant parasites, and if so, what molecular changes underlie that resistance? Answering these questions will require the kind of interdisciplinary collaboration between synthetic chemists, parasitologists, and transport biologists that this study exemplifies.

Finally, the work underscores why neglected tropical diseases benefit from basic biochemical research. Proline metabolism in T. cruzi has been studied for decades as a curiosity of parasite physiology, and only through the accumulation of that knowledge has it become possible to design targeted chemical probes that exploit this dependency. The path from fundamental biochemistry to a validated drug candidate is long and uncertain, but studies like this one, which combine broad strain coverage, mechanistic phenotyping, direct visualization of uptake, and systematic SAR, lay the groundwork that future therapeutic development will depend on. In a field where the therapeutic arsenal has remained essentially unchanged for fifty years, every new mechanistic foothold represents meaningful progress toward the goal of safer and more effective treatments for Chagas disease.

Subject of Research: Unravelling the effects of proline analogues against Trypanosoma cruzi

Article Title: Unravelling the effects of proline analogues against Trypanosoma cruzi

Article References: Ballari, M. S., Damasceno, F. S., Merli, M. L., Fargnoli, L., Pagura, L., Cricco, J. A., Silber, A. M., & Labadie, G. R. (2026). Unravelling the effects of proline analogues against Trypanosoma cruzi. Frontiers in Chemical Biology, 5, Article 1848258. https://doi.org/10.3389/fchbi.2026.1848258

Image Credits: AI Generated

DOI: 10.3389/fchbi.2026.1848258

Keywords: Trypanosoma cruzi, Chagas disease, proline transport, TcAAAP069, proline analogues, structure-activity relationship, fluorescent probe, cell cycle arrest, apoptosis-like cell death, drug discovery, neglected tropical diseases, Unravelling

What makes molecular hydrogen biologically plausible at all is a combination of unusual physical properties. The gas is extraordinarily diffusible, penetrating cell membranes and even crossing the blood-brain barrier within minutes, yet it is chemically inert enough that it does not react with most cellular components. Researchers have long proposed that its primary protective effect stems from the selective neutralization of hydroxyl radicals, the most destructive reactive oxygen species generated during inflammation and ischemia-reperfusion injury. Unlike conventional antioxidants, hydrogen leaves beneficial signaling radicals, such as hydrogen peroxide at physiological concentrations, largely untouched, which may explain why it can dampen pathological oxidative stress without abolishing the redox signaling that healthy cells depend on.

The new synthesis argues that this antioxidant activity is only the beginning of the story. Drawing on recent preclinical studies across hepatocellular carcinoma, lung cancer, and other models, the authors organize hydrogen’s anticancer effects into four coordinated axes: epigenetic remodeling, mitochondrial stress and proteostasis, tumor-suppressive cell death and cell-cycle arrest, and immunomodulation with metastatic restraint. Each axis represents a distinct molecular program that hydrogen appears to nudge in an anti-tumor direction, and together they suggest a mechanism of action far broader than simple radical scavenging.

On the epigenetic front, the review highlights evidence that hydrogen can partially reprogram cancer-associated histone modifications, particularly histone methylation dynamics. Cancer cells frequently hijack histone methyltransferases and demethylases to lock tumor suppressor genes into silent chromatin states while keeping oncogenes transcriptionally active. Preclinical data indicate that hydrogen exposure can shift these methylation patterns in ways that restore the expression of genes governing differentiation, apoptosis, and cell-cycle control. The gas also appears to modulate oncogenic non-coding RNA signaling, including microRNA networks that tumors use to suppress immune recognition and sustain uncontrolled proliferation. Because epigenetic alterations are reversible by definition, they represent an attractive therapeutic target, and a molecule as benign as hydrogen acting on them is a proposition that has caught the attention of chemical biologists.

The second axis concerns mitochondria and the proteostasis network. Tumor cells typically maintain a delicate balance of protein folding, degradation, and mitochondrial quality control to survive under hypoxic and nutrient-poor conditions. The review describes findings that hydrogen activates mitochondrial stress pathways and the unfolded protein response, a cellular alarm system that either restores proteostasis or, when the damage is irreparable, triggers programmed cell death. In cancer cells already operating near their folding and energetic limits, this additional stress can push them over the threshold into apoptosis, while non-malignant cells with greater reserve capacity appear to tolerate the same signal. This differential vulnerability is precisely what makes stress-based therapies attractive, and hydrogen’s ability to tune it without exogenous toxicity is a notable pharmacological feature.

The third axis involves the most direct anti-tumor effects: cell-cycle arrest and inflammatory tumor cell death. Preclinical studies summarized in the review show that hydrogen can halt cancer cell division at specific checkpoints, preventing the clonal expansion that drives tumor growth. In parallel, the gas appears to induce a form of inflammatory, immunogenic cell death that releases tumor antigens and danger signals, effectively turning dying cancer cells into an endogenous vaccine. This mechanism is particularly relevant to the emerging field of immuno-oncology, where the immunogenicity of tumor cell death often determines whether checkpoint inhibitors succeed or fail. A modality that can convert immunologically silent tumor killing into an active immune stimulus could, in principle, amplify the efficacy of existing immunotherapies.

The fourth and perhaps most clinically consequential axis is immunomodulation and metastatic restraint. The review details evidence that hydrogen enhances antitumor immune responses by modulating CD8-positive T-cell activity, the cytotoxic lymphocytes responsible for recognizing and destroying cancer cells. In hepatocellular carcinoma and lung cancer models, hydrogen-based interventions have been shown to influence apoptosis-related regulators and tumor suppressor signaling in ways that increase the sensitivity of malignant cells to immune-mediated destruction. At the same time, hydrogen suppresses metastatic behavior by downregulating key proliferation and immune evasion mediators, including signaling molecules that tumors use to colonize distant organs and escape immune surveillance. Because metastasis, not the primary tumor, is responsible for the vast majority of cancer deaths, any intervention that reliably restrains disseminating behavior would address the single most lethal aspect of the disease.

Beyond these four axes, the review emphasizes hydrogen’s capacity to restore dysregulated proteostatic pathways and attenuate oxidative stress-driven cellular injury in non-malignant tissue. Conventional chemotherapy and radiotherapy generate substantial reactive oxygen species that damage healthy cells, contributing to the fatigue, neuropathy, and organ toxicity that limit treatment intensity. By selectively neutralizing the most damaging radicals while preserving therapeutic redox signaling in tumor cells, hydrogen could mitigate these side effects without undermining the cytotoxic intent of the primary treatment. This dual action, sensitizing tumors while protecting healthy tissue, is what positions the gas as a pharmacologically versatile adjuvant rather than a standalone agent.

The delivery question, long a practical barrier, has seen meaningful progress. Hydrogen can be administered through inhalation of hydrogen-oxygen gas mixtures, dissolution of hydrogen-rich tablets in drinking water, injection of hydrogen-saturated saline, or topical application of hydrogen-rich creams and patches. Each route offers distinct pharmacokinetic profiles, and preclinical studies have demonstrated antitumor effects across all of them. Inhalation delivers the highest concentrations and has been explored in clinical settings for other indications, while oral and intravenous routes offer convenience for outpatient and adjuvant use. The flexibility of these delivery methods, combined with hydrogen’s favorable safety profile, removes many of the formulation barriers that stall promising molecules at the translational stage.

Despite the breadth of preclinical evidence, the review is careful to note that clinical validation remains incomplete. Most of the mechanistic data derive from cell culture and animal models, and the doses, timing, and treatment durations that produce antitumor effects in these settings have not been systematically established in human trials. The authors call for further mechanistic studies and rigorous clinical validation before hydrogen can be translated into standard oncologic practice. Nevertheless, the convergence of epigenetic, mitochondrial, cell-cycle, and immune effects under a single, non-toxic, highly diffusible molecule represents a rare pharmacological profile. As research groups worldwide begin to design the clinical studies that will test these findings in patients, molecular hydrogen stands at the threshold between laboratory curiosity and legitimate therapeutic tool, its ultimate role in cancer medicine awaiting the verdict of controlled human evidence.

Subject of Research: Molecular hydrogen as a pharmacological adjuvant modulating oncogenic signaling pathways in cancer

Article Title: Molecular hydrogen in cancer: reprogramming oncogenic signaling pathways and emerging pharmacological potential

Article References: Maity, A. K., Mallick, A., Crans, D. C., Goswami, S., & Roy, S. (2026). Molecular hydrogen in cancer: reprogramming oncogenic signaling pathways and emerging pharmacological potential. Frontiers in Chemical Biology, 5, Article 1915345. https://doi.org/10.3389/fchbi.2026.1915345

Image Credits: AI Generated

DOI: 10.3389/fchbi.2026.1915345

Keywords: molecular hydrogen, cancer therapy, epigenetic remodeling, mitochondrial stress, proteostasis, CD8 T cells, metastasis, oxidative stress, immunomodulation, cell-cycle arrest, tumor suppressor signaling, preclinical oncology

Uterine leiomyosarcoma, often abbreviated uLMS, is the most common subtype of uterine sarcoma, a family of rare malignancies that arise from the smooth muscle and connective tissue of the uterus rather than from the glandular lining. That distinction matters clinically. Unlike the far more common endometrial carcinomas, leiomyosarcomas tend to behave aggressively: they recur frequently after surgery, spread readily to distant organs, and respond poorly to the conventional chemotherapy and radiation regimens that have improved outcomes for many other gynecologic cancers. Because the disease is rare, large clinical trials are difficult to organize, and treatment options have advanced only incrementally over recent decades. Surgical removal remains the cornerstone of care, but for patients whose tumors return or metastasize, the therapeutic arsenal is thin, which is precisely why laboratory investigations of novel compounds attract such close attention.

Zerumbone is not an obvious candidate at first glance. It is a small, lipophilic molecule found in abundance in the rhizome of Zingiber zerumbet, a plant used in traditional medicine across Southeast Asia, and it is structurally related to the compounds that give ginger and turmeric their characteristic bioactivity. Over the past two decades, however, a substantial body of preclinical literature has accumulated suggesting that zerumbone can modulate a remarkably wide range of molecular targets in cancer cells. Studies cited by the Turkish team describe the compound inducing apoptosis in colorectal, leukemia, breast, ovarian, cervical, prostate, liver, lung, and brain cancer models, suppressing inflammatory signaling through pathways such as NLRP3, interfering with metastatic machinery including matrix metalloproteinases and the CXCR4-RhoA axis, and even sensitizing tumor cells to established drugs such as cisplatin, paclitaxel, 5-fluorouracil, and radiotherapy. What had never been tested, the authors note, was whether any of this activity extended to uterine leiomyosarcoma.

To fill that gap, the research team, led by Sumeyya Deniz Aybek together with Mucahit Secme and Gonca Gulbay of the Department of Medical Biology at Ordu University Faculty of Medicine, subjected SK-UT-1 cells to a battery of standard cell-biology assays. The SK-UT-1 line, generously provided by Professor Yavuz Dodurga of Pamukkale University, is a well-characterized model of human uterine leiomyosarcoma. The researchers first measured cell viability using the CCK-8 assay, a colorimetric test in which a water-soluble tetrazolium salt is reduced by metabolically active cells to a colored formazan product; the amount of dye formed serves as a proxy for the number of living cells. They then used flow cytometry with Annexin V and propidium iodide staining to quantify apoptosis, and propidium iodide DNA-content analysis to determine where in the cell cycle the treated cells accumulated. Finally, they isolated total RNA from treated and untreated cells, converted it into complementary DNA by reverse transcription, and quantified changes in the expression of genes governing cell-cycle regulation and apoptosis using quantitative real-time polymerase chain reaction.

The results were unambiguous. Zerumbone reduced the viability of SK-UT-1 cells in a dose- and time-dependent manner, meaning that the higher the concentration applied and the longer the cells were exposed, the fewer cells survived. That pattern is the classic signature of a genuine cytotoxic or cytostatic effect rather than a random fluctuation in culture conditions. Flow cytometry then revealed the mechanism behind the loss of viability: treated cells accumulated in the G0/G1 phase, the quiescent or gap phase that precedes DNA replication. In practical terms, zerumbone appears to slam the brakes on the cell division machinery before the cancer cells can copy their DNA, preventing them from progressing into S phase and onward through mitosis.

That G0/G1 arrest was followed by apoptosis, the orderly process of programmed cell death by which cells dismantle themselves without provoking inflammation. The Annexin V and propidium iodide staining demonstrated that a significant proportion of zerumbone-treated cells translocated phosphatidylserine to their outer membrane leaflet, an early apoptotic marker, and lost membrane integrity as the process advanced. The accompanying gene-expression analysis by qRT-PCR showed corresponding changes in the transcripts that regulate cell-cycle checkpoints and apoptotic pathways, providing a molecular readout consistent with the flow-cytometric observations. Together, the data sketch a coherent sequence: the compound first halts proliferation at the G0/G1 checkpoint, and when the arrested cells fail to recover, they proceed to self-destruction.

The choice of the cell cycle as the point of attack is scientifically significant. Leiomyosarcomas are known to harbor disruptions in the molecular circuitry that governs the G1-to-S transition, including amplification of genes such as CDK4 and MDM2, which has made the CDK4/6 pathway an attractive target for inhibitor drugs such as palbociclib in early-phase investigations. A phytochemical that converges on the same checkpoint, but through its own distinct set of molecular interactions, could in principle complement such targeted agents or offer an alternative where resistance develops. Prior work by other groups has shown zerumbone causing G2/M arrest in leukemia cells and G1 arrest in laryngeal carcinoma, indicating that its cell-cycle effects are context-dependent, shaped by the specific circuitry of each tumor type. The new study extends that picture to smooth-muscle-derived gynecologic sarcoma for the first time.

The Turkish team is not new to this compound. In an earlier study published in the journal Molecules, the same group examined zerumbone loaded into a metal-organic framework, a porous nanoscale carrier, and reported anticancer, antibacterial, antifungal, DNA-binding, and free-radical-scavenging activities, suggesting an interest in drug-delivery formulations that could improve the compound’s stability and bioavailability. Such delivery questions are far from trivial. Sesquiterpenes like zerumbone are hydrophobic, and achieving therapeutic concentrations in human tissues from an oral or systemic formulation is a major hurdle that no laboratory study of this kind can address. The authors themselves are careful in their framing: their data indicate that zerumbone may represent a promising candidate for further investigation as a potential therapeutic agent for uLMS, including possible use in combination therapy, not that it is a treatment.

That caution is warranted, and the path from a culture dish to a clinic is long. The present work was conducted entirely in vitro, on a single cell line, without the three-dimensional tumor models, patient-derived cultures, immune components, or animal studies that would be needed to establish whether the effect survives contact with a living organism. Pharmacokinetics, toxicity toward healthy smooth muscle and other normal tissues, dosing, and interactions with existing chemotherapies all remain unexplored for this indication. The study also required no ethics committee approval because it involved only cell cultures, and the underlying data are available from the corresponding author upon reasonable request. The work was supported by the Scientific Research Projects Unit of Ordu University under grant number A2320, and the authors declare no competing interests.

Even with those caveats, the study adds a notable entry to the growing dossier on zerumbone and underscores a broader trend in oncology research: the systematic mining of plant-derived natural products for molecules capable of re-engaging the fail-safes that cancer cells have overridden. Uterine leiomyosarcoma patients currently face high recurrence and metastasis rates with limited responsiveness to conventional therapies, and every new molecular lead expands the set of hypotheses that clinical researchers can pursue. Whether zerumbone, or a derivative or delivery system built around it, will ever reach patients with uterine sarcoma depends on the results of the preclinical and, eventually, clinical work that must follow. For now, the compound extracted from a humble wild ginger rhizome has demonstrated, under controlled laboratory conditions, that it can stop an aggressive uterine cancer cell line in its tracks and force it toward self-destruction, a result the researchers hope will justify the next round of investigation.

Subject of Research: Anticancer effects of the ginger-derived compound zerumbone on human uterine leiomyosarcoma cells in vitro

Article Title: In vitro evaluation of the Anticarcinogenic effects of zerumbone in the SK-UT-1 human uterine Leiomyosarcoma cell line

Article References: Aybek, S. D., Secme, M., & Gulbay, G. (2026). In vitro evaluation of the Anticarcinogenic effects of zerumbone in the SK-UT-1 human uterine Leiomyosarcoma cell line. Molecular Biology Reports, 53(1), Article 1617. https://doi.org/10.1007/s11033-026-12811-w

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12811-w

Keywords: zerumbone, uterine leiomyosarcoma, apoptosis, cell cycle arrest, phytochemical, SK-UT-1, G0/G1 phase, qRT-PCR, flow cytometry, natural products, gynecologic cancer, Ordu University

The researchers prepared extracts from both polished and unpolished Yoom Noon rice and applied them to two well-established colorectal cancer cell lines, HCT116 and HT29. These lines are staples of colon cancer research because they differ in their genetic backgrounds and behavior, giving scientists a way to gauge whether an effect is broad or limited to one tumor type. The team measured cell viability using the MTS assay, a colorimetric technique in which metabolically active cells convert a chemical substrate into a colored product, allowing researchers to quantify how many cells survive after treatment. Trypan blue exclusion, a classic dye-based test that marks dead cells with compromised membranes, provided an independent check on cell survival.

The results revealed a striking difference between the two cancer cell lines. Against HCT116 cells, the polished rice extract achieved a half-maximal inhibitory concentration, or IC50, of 626.74 micrograms per milliliter at 48 hours, while the unpolished extract reached an IC50 of 736.85 micrograms per milliliter. In plain terms, these concentrations were sufficient to cut the viability of HCT116 cells in half within two days. The HT29 line proved more resistant, with both extracts requiring concentrations above 1000 micrograms per milliliter to achieve the same effect. This kind of selectivity between cell lines is common in natural product research and often reflects differences in how tumor cells metabolize compounds or regulate their own survival machinery.

Beyond short-term viability, the investigators probed whether the rice extracts could undermine the long-term proliferative capacity of the cancer cells. They used a clonogenic assay, sometimes called a self-renewal assay, which challenges surviving cells to divide repeatedly and form visible colonies over days to weeks. Cancer cells that retain their ability to seed new colonies are the ones most likely to drive regrowth after treatment. Both polished and unpolished Yoom Noon rice extracts demonstrated a potent anti-proliferative ability against HCT116 and HT29 cells in this assay, indicating that the extracts do not merely slow the cells temporarily but impair their capacity for sustained self-renewal.

Perhaps the most clinically relevant findings concerned metastasis, the process by which cancer cells spread from the original tumor to distant organs and which accounts for the majority of colorectal cancer deaths. The team used wound healing assays, in which a scratch is made across a confluent cell layer and researchers track how quickly cells migrate to close the gap, along with transwell migration assays, in which cells are challenged to move through a porous membrane toward a chemical attractant. At doses that were not cytotoxic, meaning they did not kill the cells outright, the Yoom Noon rice extracts significantly suppressed both the migration and the invasion of HCT116 cells. This distinction matters because it suggests the rice compounds may interfere with the motility machinery of cancer cells at concentrations that would be safer for normal tissue.

To understand the cellular mechanisms driving the suppression of proliferation, the researchers turned to flow cytometry, a technique that passes thousands of individual cells through a laser and quantifies their characteristics one by one. Using Annexin V and propidium iodide staining, they found that treatment with the rice extracts increased apoptotic cell death in both HCT116 and HT29 cells in a dose-dependent manner. Apoptosis is the body’s programmed cell death pathway, a controlled form of cellular suicide that, unlike necrosis, avoids triggering inflammation. Many chemotherapy drugs work by pushing cancer cells into apoptosis, so a food-derived extract that promotes this pathway is of considerable interest for chemoprevention research.

Flow cytometric cell cycle analysis added a second mechanistic layer. The extracts arrested HCT116 cells at the S phase, the stage of the cell cycle during which DNA is replicated. Blocking cells at this checkpoint prevents them from progressing to mitosis and dividing, effectively putting the brakes on tumor growth. The combination of apoptosis induction and S phase arrest suggests the rice extracts act through multiple complementary routes, a pattern often seen with complex botanical mixtures that contain many bioactive compounds working in concert rather than a single isolated molecule.

Just as important as what the extracts did to cancer cells is what they did not do to healthy ones. Using a cytokinesis-blocked micronucleus assay on V79 lung fibroblast cells, the team evaluated genotoxicity, the potential to damage DNA. Micronuclei are small fragments of genetic material that break away from the main nucleus when chromosomes are damaged or missegregated during cell division, and their frequency is a sensitive indicator of DNA harm. The Yoom Noon rice extracts at concentrations of 250 to 750 micrograms per milliliter did not increase the number of micronuclei compared with untreated controls after 24 hours of exposure, indicating the extracts themselves are not genotoxic under these conditions.

The anti-genotoxic results may prove to be the study’s most provocative contribution. When the researchers co-treated the fibroblast cells with the rice extracts and Mitomycin C, a well-known mutagen, they observed a significant reduction in the frequency of micronucleated cells compared with cells exposed to the mutagen alone. In other words, the rice extracts appeared to shield DNA from a known damaging agent. This antimutagenic effect, if it holds up in further studies, would position Yoom Noon rice not only as a possible source of anti-cancer compounds but also as a candidate for chemoprevention, the strategy of using dietary or medicinal agents to stop cancer before it starts.

The authors are careful to frame this as an in vitro study, and the usual caveats apply. Extract concentrations in the hundreds of micrograms per milliliter cannot be directly translated into dietary recommendations, and compounds that survive the digestive system, cross the intestinal barrier, and reach tumor tissue in sufficient quantities remain an open question. Clinical effects would require animal studies and eventually human trials. Nevertheless, the research, supported by the Office of the Royal Development Projects Board of Thailand, establishes a credible first link between a locally significant rice strain and a suite of desirable biological activities: selective inhibition of colorectal cancer cell growth, suppression of migration and invasion, induction of apoptosis, cell cycle arrest, and protection of DNA from mutagenic damage. For a grain developed through a royal agricultural initiative in southern Thailand, Yoom Noon rice has now earned a place in the growing catalogue of natural products under scrutiny for cancer prevention and therapy.

Subject of Research: Anti-cancer and anti-genotoxic effects of Yoom Noon rice extracts on colorectal cancer cells in vitro

Article Title: Anti-cancer and anti- genotoxic potential of Yoom Noon rice: induction of apoptosis, cell cycle arrest, and inhibiting migration and invasion in vitro

Article References: Praphasawat, R., Payuhakrit, W., Surachaijarin, C., Yana, B., & Palipoch, S. (2026). Anti-cancer and anti- genotoxic potential of Yoom Noon rice: induction of apoptosis, cell cycle arrest, and inhibiting migration and invasion in vitro. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05613-x

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05613-x

Keywords: Yoom Noon rice, colorectal cancer, apoptosis, cell cycle arrest, S phase, micronucleus assay, genotoxicity, antimutagenicity, flavonoids, rice extract, chemoprevention, in vitro

Developmental senescence differs fundamentally from the senescence associated with aging and disease. During embryogenesis, selected cells enter a transient growth-arrested state in restricted tissues at precise developmental stages. Far from being a pathological accident, this programmed arrest appears to serve constructive purposes: senescent cells secrete signaling molecules that influence neighboring tissue, help remodel embryonic structures and are then cleared, often by the embryonic immune system, once their job is done. In this sense, developmental senescence behaves like a morphogenetic regulator—a temporary scaffold that helps shape organs before being dismantled. The authors of the review capture this idea in a central formulation: developmental senescence acts as a morphogenetic regulator whose activity must be tightly integrated with proliferative cues, differentiation programs and tissue-specific signaling networks.

That integration requirement is precisely where things could go wrong. Because the program must operate at the right place, at the right time and at the right intensity, the reviewers reason that any deviation—excessive senescence, insufficient senescence, senescence that lingers too long, or senescence appearing in the wrong tissue—could interfere with normal morphogenesis. A cellular program designed to sculpt tissue could, if misregulated, deform it. This logic transforms developmental senescence from a curiosity of embryology into a plausible contributor to congenital malformations, and it sets the stage for the review’s central proposal: that CHARGE syndrome, with its distinctive constellation of developmental defects, offers an unusually good model in which to investigate that possibility.

CHARGE syndrome is a rare developmental disorder whose name summarizes its most characteristic features: coloboma of the eye, heart defects, choanal atresia (blockage of the nasal passages), growth and developmental delay, genitourinary abnormalities and characteristic ear defects. The clinical picture varies widely between patients, but the underlying genetics is comparatively straightforward. Most individuals with CHARGE syndrome carry pathogenic variants in a single gene, CHD7, which encodes an ATP-dependent chromatin remodeler—a molecular machine that uses the energy of ATP to restructure how DNA is packaged and, in doing so, regulates which genes are accessible for transcription. Chromatin remodelers sit near the top of gene-regulatory hierarchies, which helps explain why mutations in CHD7 can produce effects across so many organ systems at once.

The first pillar of the review’s argument is anatomical. The authors identify a striking three-way overlap between the tissues affected in CHARGE syndrome, the regions where CHD7 is expressed during embryonic development, and the areas where developmental senescence has been observed in experimental studies. This overlapping map includes structures associated with the eye, the inner ear, the pharyngeal regions and the nervous system—the very systems most commonly disturbed in CHARGE patients. The authors are careful to note that such spatial coincidence does not establish causality. Tissues can overlap for many reasons that have nothing to do with a shared mechanism. But the overlap provides something a hypothesis needs before it can be tested: a defined set of tissues in which to look for a functional connection between CHD7 deficiency and altered senescence.

The inner ear supplies the most compelling example in the review. Developmental senescence is known to contribute to the remodeling of the developing inner ear, a structure whose intricate geometry depends on precisely coordinated tissue sculpting. CHARGE syndrome, meanwhile, frequently involves hypoplasia or complete absence of the semicircular canals, the fluid-filled loops of the inner ear that detect rotational movement and are essential for balance. In mouse models, deficiency of Chd7—the mouse counterpart of the human gene—produces major vestibular abnormalities. Putting these observations together, the authors propose that altered senescence-related remodeling could contribute to the characteristic inner-ear defects associated with CHD7 deficiency. If the cellular program that normally refines inner-ear architecture is mis-timed or mis-located in the absence of functional CHD7, the resulting structure could be underdeveloped or absent.

The second pillar is molecular. CHD7 is not an isolated actor; the review documents its intersection with well-known pathways of cell-cycle arrest and senescence, including the p53 and p21 pathways and TGFβ-related signaling. These pathways form the canonical machinery that cells use to halt division and enter a senescent state. The experimental evidence connecting them to CHD7 is particularly intriguing. In zebrafish embryos, reduced chd7 expression causes cell-cycle arrest alongside increased expression of several cell-cycle inhibitors—the molecular fingerprint of cells being pushed toward arrest. In mouse models, inappropriate activation of p53 can produce major CHARGE-like abnormalities on its own, and, more strikingly, partially reducing the dose of Trp53, the gene encoding p53, can rescue several of the developmental defects caused by Chd7 deficiency. That rescue experiment suggests the two pathways are not merely parallel but functionally entangled: dialing down one can compensate for the loss of the other.

Evidence from other developmental models reinforces the broader principle that senescence must be precisely controlled during embryogenesis. Abnormal senescence has been implicated experimentally in models involving Six1 deficiency, exposure to the drug valproic acid, maternal diabetes and trisomy 21. In each of these contexts, developmental abnormalities appear to arise when senescence occurs in the wrong location, at the wrong time or at an inappropriate level. The review extends this logic to a wider set of congenital conditions, considering whether senescence-related mechanisms might contribute to Rett syndrome, Treacher-Collins syndrome, 22q11.2 deletion syndrome, Waardenburg syndrome and related SOX10-associated disorders, and Kallmann syndrome. Here the authors urge restraint: the evidence varies considerably among these disorders, and it remains unresolved whether the cellular changes observed in them represent authentic developmental senescence or related but distinct cell-arrest states.

The authors themselves are explicit that the connection between CHD7 and developmental senescence remains a working hypothesis. As they state, the available anatomical, developmental and molecular evidence does not yet demonstrate that CHARGE syndrome is a disorder of senescence misregulation. The evidence is heterogeneous and often indirect, assembled from different organisms, different tissues and different experimental systems. What is needed now are direct experiments: mapping senescence markers across CHD7-sensitive embryonic tissues to see whether the spatial and temporal patterns of senescence are actually disturbed when CHD7 is lost, and determining how CHD7 affects chromatin accessibility, cell-cycle control and senescence-associated signaling at the molecular level. Chromatin profiling of CHD7-deficient embryonic cells, combined with single-cell analysis of senescence markers, could reveal whether the chromatin remodeler directly regulates the genetic programs that initiate or maintain developmental senescence.

There is also a therapeutic dimension, approached with appropriate caution. Senescence-modulating approaches—drugs that clear senescent cells or suppress their secretory activity—have shown benefits in some experimental models of developmental defects. But the authors emphasize that developmental senescence is itself a normal and beneficial component of morphogenesis. Bluntly suppressing it during embryogenesis could cause as much harm as the misregulation it aims to correct. Any future intervention would need to be exquisitely targeted in time, tissue and mechanism. For now, the value of the review lies in its framing: it presents CHARGE syndrome as a candidate model for understanding how the misregulation of a normally constructive developmental program could contribute to congenital disease, linking CHD7-dependent chromatin regulation to senescence pathways and embryonic tissue remodeling. Establishing a causal role will require direct functional evidence, particularly in the CHD7-sensitive structures such as the inner ear where the anatomical, developmental and molecular threads of the hypothesis converge most tightly. If those experiments succeed, they would not only illuminate a rare syndrome but also deepen understanding of how embryos use a program usually associated with aging to build new bodies.

Subject of Research: The role of developmental senescence misregulation as a candidate mechanism in CHARGE syndrome

Article Title: Developmental senescence emerges as a candidate mechanism in CHARGE syndrome

Article References: Developmental senescence emerges as a candidate mechanism in CHARGE syndrome. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: developmental senescence, CHARGE syndrome, CHD7, chromatin remodeling, morphogenesis, p53, p21, TGFβ signaling, inner ear, congenital disorders, cell-cycle arrest, embryonic development

The plant itself carries an impressive ethnobotanical pedigree. Species of the genus Carpesium have been employed in traditional Chinese medicine as antipyretic, anti-inflammatory, analgesic, antifungal, antibacterial, and antitumor remedies, and C. abrotanoides in particular has a folk-medicine history spanning antiparasitic, insecticidal, antidiabetic, antioxidant, and anti-inflammatory uses. Earlier phytochemical work established that sesquiterpenoids, fifteen-carbon terpene molecules built from three isoprene units, are the characteristic chemical signature of this species. The genus produces an unusually broad spectrum of skeletal architectures, including eudesmanolides, guaianolides, germacranolides, and even large dimeric assemblies in which two sesquiterpene units are joined together. Prior studies had also hinted at anticancer potential: an ethanol extract of the whole plant was shown to activate the Nrf2/NQO1 antioxidative pathway and trigger G2/M cell cycle arrest and apoptosis in colon cancer cells, while individual sesquiterpenoids could induce protective autophagy in various cancer lines.

To mine this chemical diversity systematically, the researchers collected twenty kilograms of dried, powdered branches and leaves from plants gathered in Baishan City in China’s Jilin Province and extracted the material with ninety-five percent ethanol. After concentrating the crude extract to more than 1.3 kilograms and partitioning it into an ethyl acetate-soluble fraction, they deployed a battery of chromatographic techniques, including macroporous resin, silica gel columns, Sephadex LH-20 gel filtration, and semipreparative high-performance liquid chromatography on both reversed-phase and chiral columns. The painstaking fractionation ultimately delivered twenty-eight pure compounds, each verified to greater than ninety-five percent purity by nuclear magnetic resonance analysis.

Structural elucidation of the five new molecules demanded a full forensic toolkit of modern spectroscopy. Carpabrotane A, for example, revealed a molecular formula of C14H18O5 by high-resolution mass spectrometry, indicating six degrees of unsaturation. Its proton and carbon NMR spectra showed an alpha,beta-unsaturated ketone, two epoxy rings spanning the C-1/C-10 and C-4/C-5 positions, and a five-membered lactone fused to the ring system, all features that together defined a rare 13-nor-germacrane skeleton, a sesquiterpene framework missing one carbon from the standard thirty-carbon count. Nuclear Overhauser effect correlations established which protons sat on which face of the molecule, and a single crystal grown from a dichloromethane-methanol mixture allowed single-crystal X-ray diffraction to lock down the absolute configuration as 1R,4R,5R,8S,10R with unambiguous precision.

The other new compounds showcased complementary structure-solving strategies. Carpabrotane B presented a tricyclic 5/7 fused carbocyclic core characteristic of a 13-nor-pseudoguaiane skeleton, and its absolute configuration was assigned by comparing its experimental electronic circular dichroism spectrum with spectra calculated using time-dependent density functional theory, a computational method that predicts how chiral molecules absorb circularly polarized light. Carpabrotane C turned out to be a twelve-carbon fragment differing from a known compound only by the migration of a hydroxyl group from position 4 to position 3, while carpabrotanes D and E were distinguished from known relatives by hydroxyl migration and by epimerization at a single stereocenter, respectively. Notably, the team also resolved long-standing ambiguities in the literature: the absolute configurations of three known compounds, including the eudesmanolide telekin, were established for the first time through X-ray crystallography and ECD calculations, correcting a gap that had persisted since their original isolation.

With all twenty-eight compounds in hand, the researchers turned to biology, screening each one for cytotoxicity against NCI-H1975 cells using the CCK-8 colorimetric assay over seventy-two hours. Two molecules dominated the results. Compound 25, the known eudesmanolide 5-alpha-epoxyalantolactone, showed an IC50 of 0.93 micromolar, while compound 13, the pseudoguaiane 2-desoxy-4-epi-pulchellin, came in at 3.68 micromolar. Both figures markedly surpass the positive control gefitinib, an approved EGFR inhibitor that managed only 9.27 micromolar against this resistant cell line. Because compound 25 had already been well characterized in prior work, including as the first small-molecule inhibitor of the annexin A2 protein, and because its natural yield was too low for extensive follow-up, the team prioritized compound 13 for mechanistic study.

What they found gives compound 13 an unusual pharmacological fingerprint. Western blot analysis after twenty-four hours of treatment revealed pronounced downregulation of three key cell-cycle regulators: Cyclin A1, which drives cells through S phase; CDC2, the kinase that propels entry into mitosis; and c-MYC, the master transcriptional controller of proliferation. Flow cytometry confirmed the functional consequence, showing a dose-dependent accumulation of cells in S phase, with a ten micromolar dose increasing the S-phase population by 1.5-fold relative to untreated controls. In parallel, levels of cleaved PARP, the canonical molecular signature of apoptosis, rose sharply, and Annexin V staining demonstrated concentration-dependent programmed cell death. Compound 13 thus operates as a dual-function agent, simultaneously halting DNA replication and dismantling the cell’s survival machinery.

This S-phase arrest mechanism is relatively uncommon among natural anti-lung-cancer agents, and the contrast with related molecules is instructive. The structurally similar 5-alpha-epoxyalantolactone induces G2/M arrest and reactive oxygen species accumulation, while santamarine, another plant sesquiterpenoid, kills lung adenocarcinoma cells through oxidative stress-mediated mitochondrial dysfunction and NF-kappa-B inhibition. A compound that combines cytostatic S-phase blockade with cytotoxic apoptosis may carry a therapeutic advantage, because forcing tumor cells through two distinct bottlenecks could reduce the likelihood that resistance mutations allow escape, a persistent problem in non-small-cell lung cancer treatment.

Comparing activity across all twenty-eight compounds also yielded preliminary structure-activity relationships that could guide medicinal chemistry. The alpha-methylene-gamma-lactone motif, an exocyclic double bond conjugated to a gamma-lactone ring, emerged as the key pharmacophore: compounds bearing it, including 25, 13, 6, and 9, were consistently the most potent, while those lacking it showed markedly reduced activity. A single hydroxyl group at position 4 or 5 proved beneficial, but multiple hydroxyls diminished potency, likely by reducing the molecules’ ability to cross cell membranes. An epoxide at positions 5 and 6 enhanced activity in compound 25 but not in its diastereomer 26, underscoring how three-dimensional orientation governs biological effect. Eudesmanolides and pseudoguaianes generally outperformed guaianolides, and the two nor-sesquiterpenoids were the least active of all.

Much work remains before any of these molecules approaches the clinic. The mechanistic studies were conducted in a single cell line, the structure-activity relationships remain preliminary, and compound 13’s molecular target has not yet been identified. Nevertheless, the study demonstrates how classical natural products chemistry, when paired with modern crystallography, computational spectroscopy, and rigorous cancer biology, can still surface genuinely novel chemical matter from medicinal plants. With five new skeletons mapped, three old configurations corrected, and a dual-mechanism lead compound in hand, Carpesium abrotanoides has earned its place on the growing list of traditional remedies whose chemistry may yet translate into modern anticancer therapeutics.

Subject of Research: Anti-NSCLC sesquiterpenoids isolated from Carpesium abrotanoides

Article Title: Sesquiterpenoids from Carpesium abrotanoides with structural diversity and anti-NSCLC activity

Article References: Tang, G.-H., Ling, L., Zhao, Z.-T., Huang, C.-J., Li, L., Wu, S.-Q., Cui, Y.-J., Jiang, L., Gan, L., Yin, S., & Pu, R. (2026). Sesquiterpenoids from Carpesium abrotanoides with structural diversity and anti-NSCLC activity. Results in Chemistry, 31, Article 103936. https://doi.org/10.1016/j.rechem.2026.103936

Image Credits: AI Generated

DOI: 10.1016/j.rechem.2026.103936

Keywords: Carpesium abrotanoides, sesquiterpenoids, non-small-cell lung cancer, natural products, cell cycle arrest, apoptosis, X-ray crystallography, structure-activity relationships, carpabrotanes, NCI-H1975, eudesmanolides, pseudoguaianes

The compound itself is a product of coordination chemistry, the branch of inorganic chemistry concerned with metal centers surrounded by organic ligands. Schiff bases, named for the nineteenth-century Italian chemist Hugo Schiff, are molecules containing an imine functional group, a carbon-nitrogen double bond formed by the condensation of an amine with an aldehyde or ketone. In this case, the ligand is 2-((allylimino)methyl)-6-methoxyphenol, derived from 3-methoxy-2-hydroxybenzaldehyde and allylamine. Three of these ligands coordinate a single cobalt ion in the +3 oxidation state, producing a mononuclear octahedral geometry in which six donor atoms surround the metal center in a three-dimensional arrangement resembling two pyramids joined base to base. This architecture is not merely aesthetic; the geometry, charge distribution, and lipophilicity of a metal complex all influence how it interacts with biological membranes, proteins, and nucleic acids, and researchers in this field have spent decades tuning these parameters to maximize anticancer activity while minimizing harm to healthy tissue.

The appeal of cobalt in this context is part of a broader renaissance in metal-based therapeutics. Cisplatin and its platinum cousins remain mainstays of chemotherapy for testicular, ovarian, lung, and other cancers, but their utility is constrained by severe side effects, including nephrotoxicity, ototoxicity, and peripheral neuropathy, as well as by the emergence of platinum resistance in many tumors. That has motivated medicinal inorganic chemists to explore other metal centers, including ruthenium, copper, gallium, and cobalt, each with distinct coordination preferences, redox behavior, and mechanisms of cellular uptake. Cobalt occupies an interesting position in biology: it is an essential trace element at the heart of vitamin B12, yet certain cobalt coordination complexes display potent cytotoxicity toward malignant cells. Previous work by some of the same authors and by other groups has shown that cobalt(III) Schiff base complexes can interfere with angiogenesis, induce oxidative stress, and disrupt signaling pathways in cancer cells, and the present study extends that line of inquiry into the cell cycle machinery and the apoptotic threshold of colorectal cancer.

Colorectal cancer itself provides a compelling backdrop for this work. It is among the most commonly diagnosed malignancies worldwide, with global burden projections indicating a substantial rise in new cases and deaths through 2040, driven in part by aging populations and shifting dietary and lifestyle patterns. At the molecular level, colorectal tumors are characterized by well-mapped disruptions of the pathways that govern proliferation and survival, including the Wnt, RAS, and p53 axes, as well as dysregulation of the BCL-2 family of proteins that controls mitochondrial apoptosis. Because the cell cycle engine and the apoptosis machinery are so central to malignant behavior, agents that can simultaneously brake the former and disable the latter are of particular interest, and this dual action is precisely what the Iranian research team set out to document.

Methodologically, the study followed a logical escalation from gross cytotoxicity to molecular mechanism. The researchers first used the MTT assay, a colorimetric test in which metabolically active cells convert a yellow tetrazolium dye into a purple formazan product, to quantify how many HT-29 cells survived exposure to increasing concentrations of [CoL3]. The resulting IC50 of 3.47 micromolar indicates that the compound kills half of the cells at a remarkably low concentration, a potency that compares favorably with many experimental metal complexes and suggests efficient cellular uptake or intracellular activation. The team then turned to annexin V-FITC/propidium iodide staining, a flow cytometry technique that exploits the fact that early apoptotic cells expose the phospholipid phosphatidylserine on their outer membrane while still excluding the DNA-binding dye propidium iodide, whereas late apoptotic and necrotic cells become permeable to both probes. This staining revealed significant increases in both early and late apoptotic populations among treated cells, establishing that the cytotoxicity observed in the MTT assay was not merely nonspecific poisoning but genuine engagement of the apoptotic program.

To understand why the cells were dying and, crucially, why they were stalling before they died, the investigators analyzed cell cycle distribution by flow cytometry, which measures the amount of DNA in individual cells and thereby assigns them to the G0/G1, S, or G2/M phases. Treatment with [CoL3] produced arrest at both the G1/S and G2/M transition points, with statistical significance at p < 0.001 and p < 0.01 respectively. The G1/S checkpoint is the gate through which a cell commits to DNA replication, and its enforcement depends heavily on the cyclin D-CDK4 and cyclin D-CDK6 complexes, which phosphorylate the retinoblastoma protein and thereby release transcription factors needed for S-phase entry. Inhibiting CDK4 and CDK6 is a validated therapeutic strategy: palbociclib, ribociclib, and abemaciclib are approved CDK4/6 inhibitors that have transformed the treatment of hormone receptor-positive breast cancer, and there is active interest in extending this class to colorectal cancer, where cyclin-dependent kinase signaling is frequently dysregulated.

The molecular data in the new study align closely with that pharmacological logic. Real-time PCR measurements showed that [CoL3] significantly reduced the messenger RNA levels of CDK4 and CDK6, with mean relative expression values of 0.62 (p < 0.05) and 0.33 (p < 0.01) compared with untreated controls. Western blotting, which detects the proteins themselves, confirmed that the downregulation propagated to the protein level, with mean protein intensities of 0.48 for CDK4 and 0.79 for CDK6, both at p < 0.001. The concordance between transcript and protein suppression strengthens the interpretation that the compound acts upstream of these kinases rather than merely destabilizing their protein products as a secondary effect, and it provides a coherent mechanistic explanation for the observed G1 phase blockade. Meanwhile, the same treatment significantly downregulated BCL2 (p < 0.01), the prototypical anti-apoptotic guardian of the mitochondrial outer membrane, which helps explain how the arrested cells were subsequently funneled into apoptosis rather than simply pausing and recovering.

Adding a computational dimension to the experimental work, the researchers performed molecular docking analyses to model how [CoL3] would fit into the ATP-binding pockets of CDK4 and CDK6, the same sites occupied by clinically approved kinase inhibitors. The docking results demonstrated favorable spontaneous binding of the cobalt complex to both kinases, reinforcing the mechanistic involvement of the compound in cell cycle inhibition and suggesting a plausible physical basis for the kinase suppression observed in the cell-based assays. Docking studies of this kind cannot by themselves prove direct target engagement in living cells, and the authors appropriately frame the computational results as supporting rather than conclusive evidence, but the convergence of docking predictions, gene expression changes, protein-level downregulation, and cell cycle phenotypes creates an internally consistent mechanistic picture.

The study also builds on the group’s own prior work with the same compound. In an earlier publication in Biochimica et Biophysica Acta, the team reported that [CoL3] downregulates cyclooxygenase-2, encoded by the PTGS2 gene, in colorectal cancer cells by inducing a G-quadruplex structure in the gene’s promoter region, a four-stranded DNA conformation that can silence transcription. Together with the present findings, this suggests that the cobalt Schiff base may be a multi-target agent, capable of simultaneously dampening inflammatory signaling, cell cycle progression, and apoptotic resistance through distinct molecular interactions. Multi-target profiles are increasingly valued in oncology because cancers are heterogeneous diseases that often evade single-agent therapies, although they also raise the stakes for selectivity, since a compound that hits many targets in cancer cells may also hit important targets in healthy ones.

As with any cell line study, the distance between these results and the clinic remains substantial. HT-29 cells are a widely used but single model of colorectal cancer, and the effects of [CoL3] on normal colonic epithelial cells, on three-dimensional tumor organoids, and in animal models will need to be established before any consideration of human testing. Questions about pharmacokinetics, biodistribution, the stability of the octahedral complex in physiological conditions, and potential off-target toxicity all await answers. Nevertheless, the study offers a rigorous mechanistic demonstration that a rationally designed cobalt(III) Schiff base can arrest colorectal cancer cells at the G1/S and G2/M checkpoints and trigger early apoptosis by suppressing CDK4, CDK6, and BCL2, and it exemplifies the strategy of borrowing validated drug targets, in this case the kinases behind some of the most successful targeted therapies of the past decade, and attacking them with an entirely new chemical scaffold drawn from coordination chemistry. For a field searching for alternatives to platinum-based drugs, that is a result worth watching closely.

Subject of Research: Anticancer activity of a cobalt(III) Schiff base complex against colorectal cancer cells via CDK4/6 and BCL2 inhibition

Article Title: CRC cell cycle arrest and early apoptosis induction by mononuclear octahedral cobalt(III) Schiff base through the inhibition of CDK4/6 and BCL2

Article References: Moshtaghian, A., Colagar, A. H., Khaleghian, A., & Zahedi, T. (2026). CRC cell cycle arrest and early apoptosis induction by mononuclear octahedral cobalt(III) Schiff base through the inhibition of CDK4/6 and BCL2. Medical Oncology, 43(10), Article 265. https://doi.org/10.1007/s12032-026-03389-1

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03389-1

Keywords: colorectal cancer, cobalt(III) Schiff base, CDK4, CDK6, BCL2, apoptosis, cell cycle arrest, HT-29, metal-based anticancer agents, molecular docking, flow cytometry, Western blotting

Organotin compounds have long intrigued medicinal chemists because of their structural versatility and pronounced biological activity, but translating that raw potency into safe therapies has proven difficult. The type and number of organic groups attached to the tin atom strongly influence both cytotoxicity and selectivity, and diorganotin species of the form R2SnX2 generally offer the best balance between killing cancer cells and sparing healthy tissue. Methyl, butyl, and phenyl substituents each tune the Lewis acidity of the central tin and the spatial shape of the complex, which in turn governs how the molecule engages biological targets. The problem, the researchers note, is that the quantitative relationship between structure and activity remains stubbornly hard to predict, which is why systematic comparisons of closely related complexes matter for the field.

To build the new compounds, the team refluxed dimethyltin oxide with a series of substituted cinnamic acids in methanol under a strict 2:1 stoichiometry. The reaction proved remarkably reliable: five distinct complexes, C1 through C5, crystallized in yields of 80 to 86 percent after the filtrate was left to stand at room temperature for several days. The mild conditions and simple operation suggest the route is a general one for constructing this class of tetranuclear tin oxide clusters. Infrared spectroscopy provided the first confirmation that coordination had occurred, with the carboxylate stretching band shifting from the 1700 to 1725 wavenumber range typical of free carboxylic acids down to about 1640, a redshift that signals successful binding to the tin center.

Single-crystal X-ray diffraction revealed that all five complexes share a striking common architecture: a ladder-like Sn4O4 core built from three edge-sharing Sn2O2 rhomboids. The central ring features notably shorter tin-oxygen bonds, between 2.024 and 2.040 angstroms, than the terminal rings, which measure 2.217 to 2.254 angstroms. That contraction reflects the triple-bridging mode of the central oxygen atoms, which link three metal centers each and impose distinctive electronic and steric constraints. Perhaps the most intriguing structural detail is that the terminal, electrophilic tin atoms are capped exclusively by methoxy ligands generated in situ from the methanol solvent, rather than by the carboxylate groups of the cinnamate ligands, a clear example of site selectivity during the self-assembly process.

The two kinds of tin centers in each cluster adopt different geometries. Those in the central ring are five-coordinate with a trigonal bipyramidal arrangement, bound to two bridging oxygens, two methyl groups, and one methoxy ligand. The terminal tin atoms are six-coordinate and distorted octahedral, carrying a chelating carboxylate in addition to the other ligands. Nuclear magnetic resonance data corroborate this picture: the 119Sn spectra of all five complexes show two resonances, near minus 136 and minus 173 parts per million, consistent with coexisting five- and six-coordinate tin centers. Thermogravimetric analysis traced decomposition through loss of methoxy ligands near 100 degrees Celsius followed by pyrolysis of the organic framework, leaving a residue whose mass matched the theoretical yield of tin dioxide.

Before any biological claims could be made, the team needed to know whether the lead complex would survive in the body’s aqueous environment. Ultraviolet-visible spectroscopy showed that C1’s absorption profile is essentially identical in ethanol and in a dilute ethanol-Tris buffer, and the spectrum barely changes across pH values from 3 to 10, a range that spans the acidic microenvironment of tumors to physiological pH. Over 24 hours at pH 7.4, absorbance declined only slightly. Hirshfeld surface analysis of the crystal packing of C1, meanwhile, quantified the intermolecular forces holding the lattice together, finding that hydrogen-hydrogen van der Waals contacts dominate at 63.3 percent, followed by carbon-hydrogen contacts at 15.9 percent and bromine-hydrogen contacts at 8.9 percent.

The mechanistic core of the study concerns how C1 interacts with DNA. Ultraviolet titration showed the complex’s 300-nanometer absorption band shifting about 5 nanometers to the red and diminishing in intensity as DNA concentration rose, behavior characteristic of a planar molecule slipping between stacked base pairs through pi-pi interactions. The calculated binding constant of 1.22 times 10 to the fourth liters per mole falls squarely in the range of established intercalators. A competitive assay using ethidium bromide, a fluorescent dye that fluoresces only when intercalated into DNA, showed dose-dependent quenching as C1 displaced the dye from the helix, with a Stern-Volmer constant of 2.04 times 10 to the fourth. Viscosity measurements sealed the case: DNA viscosity rose sharply with increasing C1 concentration, far more than with the free cinnamic acid ligand or dimethyltin oxide alone, because intercalation lengthens the helix and increases its hydrodynamic volume.

Molecular docking simulations added atomic-level texture to the picture. The optimized binding pose shows the planar cinnamate moiety of C1 slotting coplanar between DNA base pairs, while the tin-bound methyl groups split their duties: some project into the minor groove to make van der Waals contacts, and others point outward to avoid clashing with the phosphate backbone. In cell-based assays against MCF-7 breast cancer, HepG2 liver cancer, and NCI-H460 lung cancer lines, every complex beat cisplatin by a wide margin. Substituent effects were decisive. The 2-bromo derivative C1 led with IC50 values of 3.04, 1.86, and 4.78 micromolar across the three lines, likely because bromine’s electron-withdrawing character and halogen-bonding capacity improve target affinity. The 2,6-dichloro complex C4 followed closely, while the alpha-methyl derivative C5 was weakest, its electron-donating group apparently disrupting favorable interactions.

Flow cytometry revealed how the cells actually die. Using Annexin V-FITC and propidium iodide dual staining, the researchers showed that C1 triggers apoptosis in a dose-dependent fashion in HepG2 cells: 21.26 percent of the population after 48 hours at 1 micromolar, 35.6 percent at 2 micromolar, and 53.6 percent at 4 micromolar. Cell-cycle analysis showed a corresponding concentration-dependent accumulation of cells in the G2/M phase, with depletion of the G0/G1 and S populations. That arrest pattern suggests C1 interferes with mitotic machinery or introduces DNA lesions that activate the cell’s damage response; when the damage cannot be repaired, the intrinsic apoptotic pathway takes over. This coupling of cycle disruption to programmed death offers a coherent mechanistic account of the compound’s antiproliferative power.

The authors position C1 as a high-activity lead for the design of next-generation metallodrugs, emphasizing that its cytotoxicity arises from a synergistic interplay of mechanisms rather than a single target. The work also fills a gap in the organotin literature: while dibutyltin and tricyclohexyltin cinnamates have been systematically studied, dimethyltin analogues remained scarce. The Hunan-based team, funded by the Hunan Provincial Natural Science Foundation, argues that systematically mapping how substituent type and position modulate activity is the surest path from laboratory curiosity to clinical candidate. Considerable distance remains between potent in vitro activity and an approved medicine, and organotin compounds carry well-known toxicity concerns that selectivity data alone cannot resolve. Still, a molecule that is stable across physiological pH, intercalates DNA by a classical mechanism, arrests cancer cells in mitosis, and spares normal liver cells at therapeutic concentrations gives medicinal chemists a concrete scaffold to optimize.

Subject of Research: Synthesis, crystal structures, and anticancer activity of tetranuclear dimethyltin(IV)-cinnamate complexes with ladder-type Sn4O4 clusters

Article Title: Tetranuclear dimethyltin(IV)-cinnamate complexes with a ladder-type Sn4O4 cluster: synthesis, crystal structures, and anticancer activity

Article References: Zhang, Z., Jiang, Z., Tan, Y., Tan, Y., & Jiang, W. (2026). Tetranuclear dimethyltin(IV)-cinnamate complexes with a ladder-type Sn4O4 cluster: synthesis, crystal structures, and anticancer activity. Journal of Saudi Chemical Society, 30(5), Article 75. https://doi.org/10.1007/s44442-026-00129-y

Image Credits: AI Generated

DOI: 10.1007/s44442-026-00129-y

Keywords: organotin, dimethyltin, cinnamic acid, anticancer, Sn4O4 cluster, DNA intercalation, cisplatin, HepG2, apoptosis, cell cycle arrest, crystal structure, metallodrugs